SCIENTIFIC REPORTS

OPEN

Robust Identification of Alzheimer's Disease subtypes based on cortical atrophy patterns

Received: 27 October 2016
Accepted: 19 January 2017
Published: 09 March 2017

Jong-Yun Park^{1,*}, Han Kyu Na^{2,*}, Sungsoo Kim², Hyunwook Kim², Hee Jin Kim^{3,4}, Sang Won Seo^{3,4}, Duk L. Na^{3,4}, Cheol E. Han^{1,5}, Joon-Kyung Seong¹ & Alzheimer's Disease Neuroimaging Initiative[†]

Accumulating evidence suggests that Alzheimer's disease (AD) is heterogenous and can be classified into several subtypes. Here, we propose a robust subtyping method for AD based on cortical atrophy patterns and graph theory. We calculated similarities between subjects in their atrophy patterns throughout the whole brain, and clustered subjects with similar atrophy patterns using the Louvain method for modular organization extraction. We applied our method to AD patients recruited at Samsung Medical Center and externally validated our method by using the AD Neuroimaging Initiative (ADNI) dataset. Our method categorized very mild AD into three clinically distinct subtypes with high reproducibility (>90%); the parietal-predominant (P), medial temporal-predominant (MT), and diffuse (D) atrophy subtype. The P subtype showed the worst clinical presentation throughout the cognitive domains, while the MT and D subtypes exhibited relatively mild presentation. The MT subtype revealed more impaired language and executive function compared to the D subtype.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by deficits in multiple cognitive domains, and worsens across an increasingly broader range of domains as the disease progresses¹. There remains a wide spectrum of clinical features in AD patients, ranging from atypical cognitive dysfunction at presentation (starting with language, visuospatial or frontal executive dysfunction rather than memory impairment) to different rates of disease progression^{1–3}. The existence of the aforementioned distinct clinical phenotypes among patients supports the hypothesis that AD consists of several subtypes. The identification of such subtypes may potentially improve our understanding of the underlying pathomechanisms of the disease, prediction of disease course, and the development of new disease-modifying treatments⁴. A recent post-mortem neuropathological study has suggested the existence of three distinct subtypes, based on the distribution of neurofibrillary tangles⁵. However, this post-mortem subtyping approach is limited to AD patients in their advanced stages and autopsies cannot map the entire human brain.

Recent advances in neuroimaging have greatly improved AD subtyping attempts. A computational approach to subtyping has been suggested for AD patients via hierarchical clustering analysis^{6–8}, which computes the similarity between any pair of subjects in terms of cortical thickness of the whole brain^{6,7}, or a few selected neuroimaging measures⁸, and then aggregates subjects in order of descending similarity. With an arbitrary threshold of aggregation levels, this produces plausible AD subtypes. However, this approach is vulnerable to the sampling bias of a used dataset, therefore generating different subtypes even with slight changes in the sampled dataset, and the outcomes tend to cluster based on overall similarity of the cortical thickness rather than cortical atrophy patterns, as it utilizes a summation of pairwise differences.

Here we present a novel method for AD subtyping utilizing graph theory, which has high reproducibility against a random perturbation in the sampled dataset. We calculated the similarity between any two subjects in their cortical atrophy patterns across the whole brain, and clustered subjects with similar cortical atrophy patterns using the Louvain method, which was developed for modular organization extraction⁹. While hierarchical

¹School of Biomedical Engineering, Korea University, Seoul, Republic of Korea. ²Yonsei University College of Medicine, Seoul, Republic of Korea. ³Department of Neurology, Sungkyunkwan University of Medicine, Seoul, Republic of Korea. ⁴Department of Neurology, Samsung Medical Center, Seoul, Republic of Korea. ⁵Department of Electronics and Information Engineering, Korea University, Sejong, Republic of Korea. [†]These authors contributed equally to this work. [†]A comprehensive list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to C.E.H. (email: cheolhan@korea.ac.kr) or J.K.S. (email: jkseong@korea.ac.kr)

	SMC dataset			ADNI validation dataset		
	CN (n = 320)	AD (n = 225)	P-value	CN (n = 158)	AD (n = 131)	P-value
Gender, female, n (%)	188 (58.8)	149 (66.2)	0.077	84 (53.2)	57 (43.5)	0.065
Age at MRI (years)	70.0 ± 7.9	70.4 ± 9.0	0.648	76.2 ± 5.4	74.1 ± 7.4	0.007
Education (years)	11.2 ± 5.5	9.5 ± 5.8	0.001	15.9 ± 2.9	15.0 ± 2.9	0.866
K-MMSE	27.56 ± 2.55	20.96 ± 3.70	<0.001	29.17 ± 0.98	23.42 ± 2.25	<0.001
CDR-SB	0	3.08 ± 0.84	—	0	3.15 ± 0.82	—
APOE ε4 carrier (%)*	—	99/179 (55.3)	—	45 (28.5)	83 (63.4)	<0.001
APOE ε2 carrier (%)*	—	5/179 (2.8)	—	23 (14.5)	4 (3.1)	<0.001
Intracranial volume (liter)	1.31 ± 0.21	1.34 ± 0.21	0.051	1.53 ± 0.16	1.55 ± 0.18	0.249
Mean cortical thickness (mm)	2.36 ± 0.08	2.27 ± 0.11	<0.001	2.13 ± 0.10	2.00 ± 0.13	<0.001

Table 1. Demographic and clinical characteristics of the study population. Abbreviations - AD = Alzheimer's disease; MT subtype = medial temporal-predominant subtype; P subtype = parietal-predominant subtype; D subtype = diffuse atrophy subtype; K-MMSE = Korean Version of mini-mental state examination (scored out of 30); CDR = Clinical dementia rating; CDR-SB = CDR sum of boxes (scored out of 18). APOE = Apolipoprotein E. *APOE genotyping was performed in 179 of 225 patients.

clustering identifies subtypes deterministically, the Louvain method explores modular organization stochastically and is thus more robust against sampling bias.

We hypothesized that this approach would identify subtypes with distinct atrophy patterns and cognitive profiles, and applied the method to patients with 'very mild AD'^{10,11}, and compared the clinical manifestations of the resultant AD subtypes using two different datasets: the Samsung Medical Center (SMC) dataset consisting of 225 patients with AD, and 320 age, gender and education level-matched CN subjects, and the external validation dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI validation dataset) consisting of 131 AD patients and 158 matched CN subjects (see Table 1 and Supplementary Table S1 for details). The rationale for selecting very mild AD patients is because predictive markers of disease progression would be potentially more useful in patients with earlier stages, and as the disease progresses, their atrophy becomes widespread resulting in less distinctive atrophy patterns. Moreover, we limited the study to patients with minimal white matter hyperintensities in order to exclude patients with mixed Alzheimer and vascular pathology that may affect the cortical thickness.

In this present study, we established a novel subtyping approach that categorizes the early stage AD into several subtypes based on the pattern of cortical atrophy. By applying this approach to patients with very mild AD, we identified three anatomical subtypes with distinct neuropsychological profiles which were strongly associated with their characteristic atrophy patterns. The method showed high reproducibility and was also externally validated by the ADNI validation dataset.

Results

AD subtyping based on distinct cortical atrophy patterns. We identified AD subtypes by clustering AD patients based on the similarity of cortical atrophy patterns: if a subset of subjects shared a similar cortical atrophy pattern, we grouped them together. The overview of this procedure is summarized in Fig. 1. First, we computed the cortical atrophy pattern of each AD patient using normalized cortical thickness data. We then constructed a similarity matrix based on correlation coefficients of the cortical atrophy patterns for any two AD patients. Finally, clusters of AD patients with similar cortical atrophy patterns were detected using the Louvain method⁹ which is the state-of-the-art modular organization extraction method in network science. The modular organization can be found by maximizing a value of modularity that is high when the intra-modular connections are dense while the inter-modular connections are sparse (Fig. 2 and Supplementary Figure S1 middle). This subtyping produced statistically significant results (permutation testing for similarity matrix, $p < 0.001$, see Supplementary materials).

The subtypes were named after their statistically significant characteristic atrophy patterns found in the atrophy pattern comparison to CN (Fig. 2 and Supplementary Figure S1 upper row)^{6,7}. In the SMC dataset, we obtained three subtypes: an MT subtype (medial temporal-predominant atrophy, $n = 82$), P subtype (parietal-predominant atrophy, $n = 79$), and D subtype (diffuse atrophy, $n = 64$). The MT subtype features major atrophy of the medial temporal lobe including the entorhinal cortices of both hemispheres. In contrast, the P subtype's major atrophy is of the parietal cortices, superior and lateral temporal lobes and precuneus of both hemispheres. Although the atrophy extended into the frontal lobes, the depth of atrophy was greater than in the parietal lobes and precuneus. The D subtype featured sporadic atrophy over the cortices; however, the atrophy map showed that it was shallow and diffused (spanned) over the cortices, in contrast to the focal atrophy of the other two subtypes. The cortical atrophy patterns of each subtype in the ADNI validation dataset showed the same trend with those of the SMC dataset.

Neuropsychological test results. Our subtypes solely determined by MR image analysis exhibited distinct neuropsychological characteristics across the three subtypes (Table 2 and Supplementary Table S2). Overall, the P subtype showed the worst performance in overall cognitive domains, while cognitive function in the MT and D subtypes was relatively spared. The MT and D subtypes presented similar cognitive profiles except for language function, which was more disrupted in the MT subtype. Specifically, in the SMC dataset (Table 2), the

Figure 1. Overview of the proposed method. After brain surface information is extracted, resampling is performed and noise is removed. Z-scores are then computed for each subject's cortical thickness with respect to the cognitively normal (CN) subjects as their individual 'cortical atrophy'. The similarity of any pair of subjects is defined using a correlation coefficient between cortical atrophy levels of the subjects. Similarity is therefore more sensitive to the shape of the cortical atrophy patterns, rather than overall levels ($corr_{AB} > corr_{AC}$). Modular organization of subjects was extracted using the defined similarity. Note: cortical atrophy plots in the second and third boxes of the overall pipeline are depicted as an example for illustration purposes.

P subtype consisted of patients with the youngest age and highest education level compared to the other two subtypes. However, they revealed the worst cognitive profiles in terms of attention, visuospatial, visual memory, and frontal executive function. Above all, the attention and frontal executive function of the P subtype was severely impaired as determined by the worst scores in digit-span backward ($p = 0.004$), COWAT semantic fluency (animal [$p = 0.002$] and supermarket items [$p < 0.001$]), and the Stroop test ($p < 0.001$). In the RCFT copy test, not only was the score lower ($p < 0.001$) but also the time required to complete the task was longer for the P subtype patients ($p < 0.001$), exposing a significant deficit in visuospatial function. In line with this, the most severe impairment in visual memory was seen in the P subtype, as revealed by the immediate and delayed recall task in RCFT. Verbal memory function did not differ across the three subtypes in SVLT delayed recall ($p = 0.349$). When it comes to parietal lobe specific function, the dysfunction in calculation ($p = 0.053$) and ideomotor praxis ($p = 0.004$) was the worst in the P subtype patients. Even after stratifying the AD patient according to their age of onset, the P subtype exhibited the worst cognitive function in both early onset AD (EOAD, onset age < 65 years) and late onset AD (LOAD, onset age ≥ 65 years) (Supplementary Table S3).

In comparison, the MT and D subtypes exhibited relatively benign impairment. In terms of language domains, the D subtype showed relatively mild impairment in comparison to the other two subtypes (MT vs D, $p = 0.008$; P vs D, $p = 0.026$) in the K-BNT. In contrast, the MT subtype scored the worst in the K-BNT, although the impairment was not significantly lower than the P subtype ($p = 0.659$). In the Animal Category Fluency Test, the MT subtype patients showed worse performance when compared to D subtype patients ($p = 0.077$), though it did not reach statistical significance. Also the ADNI validation dataset have similar clinical characteristics across the subtypes.

Cortical atrophy hallmarks of each subtype. Each subtype revealed its own distinct cortical atrophy patterns. We therefore selected the characteristic regions of each subtype that showed severe atrophy in both the SMC dataset and the ADNI validation dataset through ROI-based analysis, and defined them as the 'hallmarks' of cortical atrophy for each subtype. The MT subtype showed characteristic atrophy patterns in the entorhinal cortex, the parahippocampal cortex, the temporal pole and the insular cortex (FDR-adjusted; Fig. 3 and Supplementary Figure S2, the lower panels), while the P subtype showed significant thinning in the precuneus and regions in the parietal lobe (the supramarginal and the inferior and superior parietal cortices, FDR-adjusted; Fig. 3 and Supplementary Figure S2, the upper panels). When it comes to the subcortical structures, the volume of the hippocampus and amygdala was smaller in the MT subtype (Supplementary Table S4). Compared to the other two subtypes, the atrophied region in the D subtype was relatively unclear and sometimes failed to show convergent findings in both datasets. In general, hallmarks in the left and the right hemispheres showed a similar trend. The summary of the hallmark analysis results can be found in Supplementary Table S5. We note larger atrophy levels in the D subtype in the ADNI validation dataset compared to those in the SMC dataset (Fig. 2 and Supplementary Figure S1).

Reproducibility of subtyping. Our proposed method is highly reproducible (SMC dataset: 92.25%; ADNI validation dataset: 92.53%) and consistent on average for 10 subsets with 10% random removal. We extensively compared the proposed method with the following two methods: hierarchical clustering (HC) and the Louvain

Cortical Atrophy Patterns

Figure 2. Cortical atrophy patterns for three AD subtypes using the SMC dataset: MT (medial temporal-predominant), P (parietal-predominant), and D (diffuse) subtypes. Modular organization of the subjects was achieved using defined similarity and reordered to illustrate subtyping where each square captures a subtype border. Group comparison results of cortical thicknesses between each subtype and CN was corrected using random field theory and regions with corrected $p < 0.001$ are visualized ($p < 0.05$ for the D subtype) with covariate age, gender and education. (upper row). Atrophy map shows medians of the cortical atrophy (z-scores) in each subtype ($-0.6 \leq z \leq -0.3$) (lower row).

method based on the correlation and Euclidean distance between subjects. Our proposed method with correlation coefficients between cortical atrophy patterns excelled HC since it had the highest modularity and high reproducibility (92.25% reproducibility, Table 3). The hierarchical clustering (HC) method has lower reproducibility than our method (83.42% reproducibility, Table 3). Since HC deterministically clusters subjects, the subtyping results can be biased to the sample distribution while the Louvain method has increased chance to find optimal subtyping and leading to the higher reproducibility. Our extensive analysis (Supplementary Tables S6 and S7) also showed that using correlation coefficients lead better clinical association.

Discussion

In this paper, we proposed a new subtyping approach that uses similarity in cortical atrophy patterns based on correlation coefficients and the Louvain method for clustering subjects. The proposed method successfully categorizes very mild AD into clinically distinct anatomical subtypes with high reproducibility.

Our study holds several methodological strengths over previous approaches⁶. First, our method provides highly reproducible subtypes (>90%), as tested in two different ethnic populations and subsets of samples with 10% random removal. Moreover, despite the strength of the magnetic field of MR scanners are different with each other in two datasets (the SMC dataset: 3T, the ADNI validation dataset: 1.5T), the subtyping results were fairly reproduced. Second, our strategy is based on cortical atrophy patterns rather than raw cortical thickness and therefore subjects within a single subtype naturally share similar cortical atrophy patterns. Third, we employ the Louvain method for clustering, a tool known to be accurate and efficient. Fourth, there is no heterogeneous subtype that consists of the 'leftovers' or those cases that cannot be classified into a distinct subtype. In this regard, our approach addresses the limitations of a previous study that classifies such cases as one subtype, which may

	AD subtypes				Comparison between AD subtypes			
	MT subtype	P subtype	D subtype	Total	P-value ^a	MT vs. P	MT vs. D	P vs. D
SMC dataset	n = 82	n = 79	n = 64	n = 225				
Attention								
Digit-span forward	−0.25 ± 1.15	−0.36 ± 1.10	−0.24 ± 1.05	−0.29 ± 1.10	0.740	0.513	0.946	0.498
Digit-span backward	−0.49 ± 1.03	−1.15 ± 1.18	−0.73 ± 1.59	−0.79 ± 1.28	0.004	0.001	0.261	0.055
Language								
K-BNT	−2.04 ± 1.60	−1.91 ± 2.31	−1.19 ± 1.63	−1.75 ± 1.91	0.019	0.659	0.008	0.026
Visuospatial function								
RCFT copy, score	−0.65 ± 1.76	−4.53 ± 5.29	−0.73 ± 1.19	−2.05 ± 3.84	<0.001	<0.001	0.890	<0.001
RCFT copy, time	0.10 ± 1.12	−0.60 ± 1.59	0.46 ± 0.76	−0.05 ± 1.31	<0.001	<0.001	0.093	<0.001
Visual memory								
RCFT, immediate recall	−1.70 ± 0.92	−2.11 ± 0.69	−1.61 ± 1.08	−1.82 ± 0.92	0.002	0.004	0.561	0.001
RCFT, delayed recall	−1.78 ± 0.78	−2.20 ± 0.65	−1.72 ± 0.91	−1.91 ± 0.80	<0.001	0.001	0.636	<0.001
RCFT, recognition	−1.95 ± 2.08	−1.76 ± 1.53	−1.84 ± 2.04	−1.85 ± 1.88	0.817	0.527	0.734	0.803
Verbal memory								
SVLT, immediate recall	−1.24 ± 1.18	−1.67 ± 1.26	−1.21 ± 1.04	−1.38 ± 1.19	0.027	0.020	0.897	0.021
SVLT, delayed recall	−2.15 ± 1.36	−2.40 ± 0.97	−2.44 ± 1.65	−2.32 ± 1.33	0.349	0.240	0.195	0.845
SVLT, recognition	−1.67 ± 1.35	−2.3 ± 1.75	−1.66 ± 1.36	−1.89 ± 1.53	0.012	0.008	0.961	0.013
Frontal executive function								
COWAT, semantic-animals	−1.36 ± 0.99	−1.68 ± 1.11	−1.05 ± 0.95	−1.39 ± 1.05	0.002	0.049	0.077	<0.001
COWAT, semantic-supermarket	−0.98 ± 0.90	−1.53 ± 0.84	−1.10 ± 0.85	−1.21 ± 0.90	<0.001	<0.001	0.379	0.004
COWAT, phonemic with 3 letters	−0.64 ± 1.29	−0.75 ± 1.30	−0.31 ± 1.75	−0.60 ± 1.43	0.216	0.634	0.205	0.085
Stroop test, color reading	−1.23 ± 1.35	−3.31 ± 1.61	−1.27 ± 1.28	−2.01 ± 1.74	<0.001	<0.001	0.870	<0.001
Calculation ^b	9.66 ± 2.81	9.03 ± 2.88	9.15 ± 3.35	9.28 ± 2.99	0.053	0.016	0.210	0.217
Ideomotor praxis ^b	3.96 ± 1.33	3.44 ± 1.62	3.85 ± 1.25	3.74 ± 1.44	0.004	0.001	0.110	0.071

Table 2. Neuropsychological test scores of each AD subtypes SMC dataset. ^aOne-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) post hoc test was used for comparison of continuous variables except for the calculation test. P-values of post hoc tests are shown in bold where statistically significant. ^bIn tests where standard scores were not available, analysis of covariance (ANCOVA) followed by Fisher's least significant difference (LSD) post hoc test was used for comparison among the AD dementia subtypes. MT subtype = medial temporal-predominant subtype; P subtype = parietal-predominant subtype; D subtype = diffuse atrophy subtype. K-BNT = Korean version of Boston Naming Test; RCFT = Rey-Osterrieth complex figure test; SVLT = Seoul verbal learning test; COWAT = controlled oral word association test. Standard scores (z-scores) were used in comparison as age, sex, and education level in years were different among the AD dementia subtypes.

be a source of bias⁵. Lastly, we externally validated our methods by applying our subtyping strategy to the ADNI validation dataset and achieved similar results to those of the SMC dataset.

The proposed subtypes have distinct neuropsychological characteristics in the SMC dataset (Table 2). Patients in the P subtype had an earlier onset of disease and exhibited the worst clinical outcomes among the three subtypes in most cognitive domains, except for verbal memory function. These findings may be explained by the regions involved in cortical atrophy in the P subtype: the precuneus, bilateral posterior parietal cortices (inferior and superior parietal lobules), and bilateral dorsolateral frontal areas. The most representative function of the parietal cortex is spatial processing^{12–14}, and deficit in visuospatial function and visual memory was accordingly evident in the P subtype. Besides visuospatial function, the parietal lobe (both lateral parietal cortices and the precuneus) is also involved in selective attention and working memory¹⁵, and therefore correlates well with overall deterioration in the P subtype. In particular, the precuneus, in which atrophy was most evident in the P subtype, plays a key role in a wide range of higher-order cognitive functions, such as executive function, visuospatial imagery, and self-processing operations¹³. In addition, the dysfunction in calculation ($p = 0.053$) and ideomotor praxis ($p = 0.004$), which are regarded as parietal specific function^{16–18}, was the worst in the P subtype patients.

In comparison to the P subtype patients, the MT and D subtype patients showed better neuropsychological performances and their overall cognitive profile were quite similar. However, even in these two relatively mild anatomical subtypes, MT subtype patients showed worse performances in language domain (K-BNT), processing speed in visuospatial constructive function (RCFT copy time) compared with the D subtype patients. Moreover, MT and D subtypes differed in the average age, gender distribution and the pattern of gray matter atrophy, implying that MT and D subtype may be a distinct subtype. However, there lies a possibility that MT and D subtype may be quite difficult to distinguish mainly based on their neuropsychological performances. This also implies that differentiation of AD subtypes (based on the proposed cortical atrophy patterns) may be helpful when enrolling participants and analyzing data in future clinical trials. If a single group consists of both MT and D

Figure 3. Cortical atrophy hallmarks in each AD subtype in the SMC dataset. Normalized cortical thicknesses of the subtype-specific hallmark regions are shown: P subtype hallmarks (upper right), MT subtype hallmarks (lower right) and D subtype hallmarks (left). Bar colors represent specific subtypes: blue (MT subtype), red (P subtype) and yellow (D subtype), where asterisks indicate statistical significance (permutation-based ANCOVA, FDR-adjusted).

subtypes, the response to treatments or underlying pathophysiology might be distinctly different, and the outcomes may be affected accordingly.

Some may argue that the aforementioned distinct cognitive profile may be a result of generally worse cognition or stage of disease progression rather than reflecting a specific clinical subtype. In order to avoid this issue, we introduced the concept of correlation coefficients to subtype AD patients based on the similarities in the overall cortical thinning patterns (predominant atrophy pattern) rather than based merely on the absolute values of cortical thickness. Moreover, we included the patients with CDR-SOB ≤ 4 (i.e., very mild AD) to narrow the stage of disease progression so as to avoid classification of AD into subtypes with different stage of disease. In this present study, the disease duration, the MMSE, and CDR-SOB scores which are known to reflect the general cognitive status and stage of disease did not show significant difference across the subtypes. Consequently, our proposed subtypes appear to reflect specific clinical subtype rather than a result of AD with different stage of disease.

Of note, the P subtype shares several common core features with the hippocampal-sparing subtype, a neuropathologically defined subtype characterized by aggressive disease progression, earlier age of onset, and cortical atrophy involving the parieto-frontal cortices^{5,19}. In addition, there also exists similarities between our MT subtype and the limbic-predominant AD in terms of female predominance, relatively late age of disease onset, and the atrophy pattern restricted to the medial temporal lobe^{5,19}. Intriguingly, the MT subtype showed more atrophied hippocampus and amygdala compared to the P subtype (Supplementary Table S4), which was also a core finding in the limbic-predominant and hippocampal-sparing AD¹⁹. This substantial overlap between neuropathology studies and ours lend greater weight to the subtypes identified in this present study.

Despite numerous attempts to classify AD into multiple subtypes, there have been few effective measures proposed to accomplish the task^{6,8,20,21}. Some of the recent studies exploited gray matter volume of a few selected regions of interest⁸ or the whole brain²¹. The study called CHIMERA²¹ proposed a notable probabilistic subtyping framework using the volume of 80 regions of interest. The proposed probabilistic method is promising but its main limitation is that it is not suitable for the high-dimensional data like our whole brain cortical thickness data. Murray *et al.* proposed pathological AD subtypes by sorting along an axis that represents the ratio of hippocampal to cortical neurofibrillary tangle density in a clinicopathological cohort of 889 cases of AD^{5,22}. Although this study provided AD subtypes with a relatively strong level of evidence, it was limited as the subtyping was performed post-mortem, representing AD subtypes only in their advanced stages. Although, the distinct cortical atrophy patterns across the pathological subtypes was also investigated in a follow-up neuroimaging study by utilizing the first MRI after diagnosis of AD¹⁹, there still remains a limitation in that the subtyping itself was performed based on post-mortem tauopathy. This approach also cannot be used to determine which subtype an early stage

Dataset	Methods	Q	Reproducibility
SMC dataset	Hierarchical Clustering (Euclidian Distance)	—	83.42%
	Hierarchical Clustering (Correlation)	—	86.87%
	Louvain method (Euclidian Distance)	0.0110 (0.1891 ^a)	— ^b
	Louvain method (Correlation)	0.2202	92.25%
ADNI validation dataset ^c	Hierarchical Clustering (Euclidian Distance)	—	72.03%
	Hierarchical Clustering (Correlation)	—	89.03%
	Louvain method (Euclidian Distance)	0.0235 (0.1665 ^a)	— ^b
	Louvain method (Correlation)	0.2464	92.53%

Table 3. Comparison of modularity and reproducibility for subtyping methods. ^aTo compute the modularity value, similarity matrix is required but it also affects the modularity value Q. Thus, we computed the value using the same similarity matrix with our method in order to observe the effects of the modular organization only. ^bThe Louvain method with the Euclidian distance raised only two subtypes and thus it is unfair to compare its reproducibility with other methods. ^cThe ADNI validation dataset contained an unknown subtype and we excluded this type in the reproducibility analysis.

AD patient should be assigned to, and autopsies cannot map the entire brain as it is a region-of-interest-based method. In contrast to the post-mortem study, subtyping using MR imaging is non-invasive and thus applicable to living patients. Our findings also provide evidence that subtyping can be achieved for very early stage AD, and thus may be useful for early treatment intervention.

Our proposed method is highly reproducible, showing an average consistency of 92.25% and 92.53% for 10 subsets with 10% random removal in the SMC dataset and ADNI validation dataset, respectively. Our analysis (Table 3) revealed that the Louvain method for modular organization extraction improves the reproducibility, showing higher reproducibility compared to the hierarchical clustering method (SMC dataset, 83.42%; ADNI validation dataset, 72.03%). Since the hierarchical clustering method clusters subjects deterministically, it tends to be vulnerable to changes in sample size or distribution. In contrast, the Louvain method stochastically explores the optimal clustering configuration in order to maximize the modularity value, thereby increasing the chance to identify optimal subtyping and thus leading to the higher reproducibility.

Our analysis (Table 3) showed that the subtyping strategy utilizing the correlation coefficients tends to classify AD into distinctive subtypes better than approaches based on Euclidean distance. This superiority arises from the nature of the correlation coefficient itself in that the absolute values of cortical thickness can be automatically controlled in the operation process and thus using correlation coefficients is useful to capture similarities in cortical thinning patterns between the two subjects, rather than the differences in thickness, and is therefore more sensitive in distinguishing the pattern difference (Fig. 1). We emphasize that our D subtype is neither a leftover group (i.e. not classifiable into MT or P subtypes) nor a group defined by the level of cortical thinning. Since the proposed method clusters all subjects simultaneously based on the similarity of the cortical atrophy patterns, patients with the D subtype share their own distinct atrophy pattern that is distinguishable from the other subtypes. Also since we employed the correlation coefficients as a similarity metric, the overall cortical thinning was not a factor for clustering, while the Euclidean distance-based measure could be affected by the sum of differences in the cortical thickness. Thus, we further compared our method with the Euclidean distance-based Louvain method. The Louvain method based on the Euclidean distance resulted in two subtypes; one with a low level of overall cortical thinning and the other with a high level, since the Euclidean distance-based method integrates overall atrophy of the cerebral cortex. Although the low-level atrophy subtype can be classified into the MT and P subtypes, the difference in cognitive profile was less clear than with our method (Supplementary Tables S6 and S7).

Another novelty in our method is using the z-score of cortical thickness normalized by the distribution of cortical thickness in the CN group, instead of using raw cortical thickness. The raw cortical thickness is a snapshot of the current remnants; however, for the cluster analysis of the cortical thinning pattern, it is better to measure the extent of cortical atrophy in each patient instead. Generally, it is not possible to observe the extent of cortical thinning within a single MR image, as we cannot determine the cortical thickness of the brain before AD diagnosis. In this study, we estimated the level of cortical atrophy by normalizing the remnant cortical thickness with the distribution of cortical thickness in the CN group. The standard deviation for each brain region may account for inter-subject variability; in cases where large inter-subject variability resides, even when the remnant is small, it would not be considered as severe cortical atrophy (Fig. 1). Since this procedure considers the inter-subject variability, where the large inter-subject variability lies, the resultant z-score is not low even when the subject's cortical thickness is thinner than the mean of the CN subjects. Thus, in the resultant cortical atrophy patterns, the deep or shallow atrophy is determined not only by the cortical thinning of the patient, but also by the inter-subject variability in the CN group. We believe that the use of this z-score improves subtyping performance.

Although the heterogeneity of AD is not a new concept, the underlying mechanisms that can account for the selective vulnerability in topographic distribution of brain atrophy in each AD subtype remain elusive. The difference in tau pathology, functional networks, metabolism may play a major role in selective vulnerability²³, but we cannot support any of the previous hypotheses with our data of this present study. In this regard, we at least aim to suggest the “hallmarks” of cortical atrophy for each subtype so that they may serve as a viable start point in future studies. In the MT subtype, the entorhinal cortex, the parahippocampal cortex, the temporal pole and the insular cortex were selected through ROI-based analysis as hallmarks. Atrophy in these structures are known to produce selective vulnerability presented in AD patients, especially responsible memory dysfunction²⁴. Moreover,

temporal pole atrophy is known to play a prominent role in naming impairment, which was also evident in our study²⁵. In the P subtype, the precuneus, the supramarginal, inferior parietal and superior parietal cortices were selected as hallmarks. Consistent with the damage in these structures, the P subtype showed significant impairment throughout the overall cognitive function, especially for visuospatial and executive function^{12–15}. Of note, the D subtype revealed a balanced atrophy pattern rather than involving focal specific region. Although significant thinning near the central sulcus was observed in the D subtype, this finding might not be a result of selective vulnerability in the region. Rather, this may be a relative finding as the D subtype tends to reveal shallow but diffuse atrophy throughout the cortices, while paracentral cortices are less affected in the other subtypes. Though we cannot point out a selectively vulnerable region for this subtype, this balanced atrophy pattern itself may act as a hallmark for the D subtype.

The hallmarks may provide not only supportive evidence that subjects clustered by our approach share a specific atrophy pattern, but also informative criteria to distinguish subtypes in future. As an example, if a certain subject presents with severe alteration of cortical thickness in the precuneus and a few parietal regions, they may be suspected to be a P subtype patient, since the precuneus and a few parietal regions are hallmarks of the P subtype.

As neurodegenerative diseases are hypothesized to propagate along the brain network, the possible network involved in each subtype may be important in understanding the heterogeneity of AD. In light of the pattern of atrophy, the AD pathology of the P subtype appears to be centered preferentially along the default mode network. The parietal lobe is well-known to be responsible for higher cortical function in human and thereby associated with high metabolic demand, but at the same time, known as the most vulnerable region due to thin myelination^{7,26}. When considering that the degree of parietal vulnerability is highly variable across individuals^{26,27}, we surmise that patients who show such vulnerability may develop P subtype of AD dementia. By contrast, the anterior medial temporal network, a network involved in some aspects of declarative memory²⁸, appears to be preferentially disrupted in the MT subtype when taking the memory and confrontation naming dysfunction into consideration. However, further connectivity studies are necessary in order to find the vulnerable networks of each subtype.

We note several limitations to our proposal. First, the regularization parameter, γ , for the Louvain method was set empirically, which may act as a potential bias. We followed the previous post-mortem neuropathological study⁵ for the target number of subtypes and controlled the parameter in order to obtain three subtypes. However, as shown in our experimental results, the proposed method provides consistent subtyping across different population sets with distinct cortical atrophy patterns and the associated neuropsychological tests scores were validated from a clinical perspective. Second, pathological confirmation was not performed in this study. We validated our subtyping approach using the ADNI validation dataset and provided supporting evidence using neuropsychological tests, inter-group consistency of subtypes, and distinct cortical regions of each subtype (hallmarks). Third, we cannot exclude the possibility that the cortical atrophy was affected by non-AD pathology. In order to minimize the contribution of factors related to cortical atrophy other than AD, we used probable AD patients with minimal WMH only and excluded those with moderate or severe WMH as well as patients with a past history that may contribute to cognitive deficit. Although this may limit the generalizability of the study, as nearly half of all AD patients tend to reveal moderate or severe WMH^{29–31}, this aided in analyzing the cortical atrophy patterns affected mainly by AD itself. Fourth, our study cannot explain the mechanisms of selective vulnerability in each subtype. Instead, we listed up the core atrophied subregions of each subtype (hallmarks) in order to identify regions that physicians could focus on when designing future studies. Fifth, our study did not include the subcortical regions and other important biomarker including the amount of amyloid beta and tau protein deposition. For example, it is well-known that the volume of hippocampus and amygdala was associated with cognitive performance of dementia patients³². Though we did not include the subcortical regions, it may be accompanied with the structure nearby in the medial temporal lobe. Our study excluded the biomarkers beyond neuroimaging though they are important and reliable diagnostic biomarkers, since we believe that the neuroimaging biomarkers from the MR imaging is more appropriate for screening the population. Sixth, we cannot exclude the possibility that the distinct clinical characteristics across the subtypes might have been affected by the age of onset (i.e., EOAD and LOAD). However, it should be noted that the overall cognitive profiles of each subtype were similar even after stratifying the subtypes according to age of disease onset, indicating that our findings are not simply a result of disproportional distribution of EOAD and LOAD patients across subtypes. Lastly, no longitudinal follow-up study was performed in this setting, limiting the potential value as we cannot determine whether the proposed subtypes can be used for the prediction of disease progression.

Summary and Conclusion

We propose a novel subtyping method for very mild AD patients. The resulting subtypes are strongly associated with neuropsychological performance and each has a distinct cortical atrophy pattern. The suggested method has high reproducibility in comparison to previously suggested methods. However, it remains to be determined in future studies whether this subtyping approach can be applied at more advanced stages (mild, moderate, severe AD) or whether proposed subtypes in very mild AD may entail differing predictive values for progression trends in AD. Applying this subtyping approach to other diseases and diagnostic purposes may also yield further benefit.

Materials and Methods

Subject recruitment and MR image acquisition. In the SMC dataset, we retrospectively analyzed the data of 225 patients with AD and 320 age, gender and education level-matched cognitively normal subjects (CN) at Samsung Medical Center from June 2006 through December 2013. Written informed consent for the study was obtained from all patients and the protocol was approved by the Institutional Review Board of Samsung Medical

Center. This study followed the tenets of the Declaration of Helsinki in 1964 and all subsequent revisions. We obtained high-resolution T1-weighted MR images using a 3.0T Philips Achieva.

In order to provide additional evidence that our findings are accurate and applicable to the general AD dementia population, we applied our subtyping approach to the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner. The primary goal of ADNI has been to test whether serial MRI, positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD (for updated information, see www.adni-info.org) (see Supplementary Figure S5 for details). A total of 131 patients with AD and 158 age, gender and education level-matched CN subjects were selected for the ADNI validation dataset. The T1-weighted MR images for the subjects were recorded following the ADNI acquisition protocol³³. We used images acquired at 1.5T for the ADNI validation dataset. In both datasets, we included AD patients fulfilling the following criteria: clinical dementia rating sum-of-boxes (CDR-SB) less than or equal to 4 (very mild AD)^{10,11}, MMSE score less than 27^{34,35}, and minimal white matter hyperintensities (WMH)^{30,31}. The detailed subject inclusion/exclusion criteria and MR protocol are described in the Supplementary material.

Neuropsychological assessment. The cognitive function of each participant in the SMC dataset was assessed using a standardized neuropsychological assessment tool, the Seoul Neuropsychological Screening Battery (SNSB)^{36–38}. The SNSB includes tests designed to measure attention, language, praxis, visuoconstructive function, verbal and visual memory, and frontal executive function^{36,37}. We used standard neuropsychological test scores (z-scores) because the age, sex, and education levels were different between the AD dementia subtypes. The z-scores were derived based on age- and education-adjusted norms^{36,37}. In addition to the SNSB, we also used the Korean version of the Mini-Mental Status Exam (K-MMSE) and CDR-SB. The ADNI neuropsychological assessment procedures have been previously described^{39,40}. We used a modified Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog)^{41,42}, the most widely used standard cognitive measure in the AD population, and included the Digit Span Test, BNT⁴³, Rey Auditory Verbal Learning Test (RAVLT)⁴⁴, Clock Drawing Test⁴⁵, Trail Making Test (TMT)^{46,47}, Digit Symbol Substitution Test⁴⁸ and Category Fluency Test⁴⁰. Composite scores including ADNI-EF and ADNI-Mem were also used^{49,50}.

Image preprocessing. Figure 1 depicts a brief overview of the proposed analysis pipeline. We computed the cortical thickness from T1-weighted images using FreeSurfer v5.1.0^{51,52}. Following the recommended reconstruction pipeline, we visually checked and corrected image segmentation. FreeSurfer extracts various surfaces from T1-weighted images, including the pial surfaces (outer boundary of the gray matter), white matter surfaces (boundary between gray and white matter), and spherically deformed surfaces which are registered to the FreeSurfer's standard subject. Due to inter-subject variability of brain shapes, we resampled the surfaces with 40,962 vertices for each hemisphere using our in-house software⁵³. We then removed artifacts in the cortical thickness data using the Laplace-Beltrami (LB) operator, similarly to past studies^{53–55}.

Estimation of cortical atrophy patterns using z-scores. For each vertex of a cortical surface, a z-score was computed with respect to the cortical thickness distribution in the CN group: $z_i^{AD_j} = (c_i^{AD_j} - \mu_i^{CN}) / \sigma_i^{CN}$, where $c_i^{AD_j}$ is the cortical thickness value of the i -th vertex of the j -th AD patient, μ_i^{CN} is the mean cortical thickness of the i -th vertex in the CN group, and σ_i^{CN} is its standard deviation. This z-score represents the extent of cortical atrophy for a specific location. Once the relative extent of cortical thinning is calculated for all vertices sampled over the smooth cortical surface, we then define a cortical atrophy pattern of the j -th AD patient by concatenating $z_i^{AD_j}$, for $i = 1, 2, \dots, 81924$.

Similarity matrix construction and subtyping using the Louvain method. We constructed a similarity matrix for the AD group using correlation coefficients between cortical atrophy patterns of any two subjects. We excluded the non-cortical tissue while computing the correlation coefficients. For cluster analysis of the AD patients, we employed the Louvain method⁹ which was developed for modular organization extraction in network science. The modular organization in a large network can be found by maximizing a value of modularity which is high when the intra-modular connections are dense while the inter-modular connections are sparse. In our problem setting, dense intra-modular connections imply high similarity of the cortical atrophy pattern between subjects in a module. The Louvain method is not only efficient for larger networks, but also very accurate; for a few large networks, its value of modularity was the highest among the current common modular organization extraction methods⁹. Since the Louvain method is based on a greedy optimization method, the clustering results can vary slightly. To resolve this issue, we employed a 'major voting' scheme, in which we extracted modular organization N times, and labeled a subject with the most frequently assigned cluster (Supplementary Figure S4). The Louvain method has a resolution parameter, γ (gamma), which controls the number of clusters. In our experiments, we controlled it to obtain three subtypes based on the previous post-mortem study⁵ ($N = 1000$ and $\gamma = 0.9$). We also estimated statistical significance of the Louvain method based on a permutation test of the similarity matrix (see Supplementary material). We used the implementation in the brain connectivity toolbox for the Louvain method⁵⁶.

Comparison of the proposed method with other methods. To compare with the previous study⁶, we followed the same method as possible as we can; the only difference is that we used our estimated cortical atrophy instead of cortical thickness for fair comparison and adopt both correlation coefficient and Euclidean distance. The latter was for investigating the effects of the correlation coefficients. Since the Louvain method requires

similarity measures, we transformed the Euclidean distance into the similarity with monotonically decreasing function ($w_{ij} = \exp(-d_{ij}/\alpha)$, where d_{ij} is the Euclidean distance between the i th and j th subjects, and α is a regularization factor). We evaluated their performance in terms of three different measures: modularity Q , reproducibility, and effectiveness of clinical interpretation. The reproducibility captures how a method provides consistent results over different datasets, which was measured by a fraction of consistently assigned subjects to each subtype on average. We divided the dataset into 10 subsets and repeated our method over them 10 times excluding one subset in turn. We then computed the average fraction over 10 runs. It is also important that resulting subtypes share a certain neuropsychological characteristics to be clinically useful.

Inter-dataset consistency of subtyping. We tested how significantly each subtype obtained in the SMC dataset was matched with its corresponding subtype obtained in the ADNI validation dataset using permutation testing. We sought to determine whether the average similarity evaluated between the correctly matched subtypes (e.g. the MT subtype in the SMC dataset and the MT subtype in the ADNI validation dataset) was higher than the other random matchings using permutation testing (see Supplementary materials for details).

Cortical atrophy hallmarks of each subtype. We defined ‘hallmarks’ of cortical atrophy for each subtype, which are the characteristic regions with severe atrophy. We first performed the ROI-based analysis of cortical thickness, where 34 cortical ROIs are pre-defined for each hemisphere⁵⁷. We obtained normalized thickness values by dividing the average thickness of each ROI by the mean cortical thickness of the entire cortices. As our subtyping method clusters subjects based on the shape of cortical atrophy patterns rather than the level of overall cortical atrophy, a simple mean value of cortical thickness in a subtype does not represent the characteristics of the subtype. We compared the normalized cortical thickness of each ROI using permutation-based ANCOVA (see Supplementary material), controlling for age, gender and education level. We then selected hallmark regions that survived after the false discovery rate (FDR) procedure^{58,59} and revealed a distinct cortical atrophy pattern for each subtype.

Statistical Analysis. Comparison of demographic data or standardized neuropsychological test scores between the three subtypes of AD was assessed using χ^2 test or one-way analysis of variance (ANOVA), and a Least Significant Difference (LSD) test was conducted for post-hoc analysis. For comparison of neuropsychological test scores between the AD subtypes in the ADNI validation dataset, permutation-based analysis of covariance (ANCOVA) was used, adjusted for age, gender, and education (see Supplementary Material). All statistical operations for the demographic data and standardized neuropsychological test scores were performed using PASW Statistics 21 (SPSS, Chicago, IL) software except for permutation-based ANCOVA. Two-sided p -values less than 0.05 ($p < 0.05$) were considered statistically significant. We employed random field theory⁶⁰, and permutation-based ANCOVA for cortical atrophy comparisons (see Supplementary Material). All statistical operations and analyses of MR images were conducted using MatLab (Version 2014b, Mathworks, Natick, USA), SurfStat (RFT and visualization of cortical atrophy) and our in-house software (permutation testing).

Data availability. We provided our in-house analysis software in our webpage (http://bia.korea.ac.kr/software/AD_subtyping/) along with the pre-processed test data set. Using the provided test data set, one can reproduce our results.

References

1. Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. *Lancet* **368**, 387–403, doi: 10.1016/S0140-6736(06)69113-7 (2006).
2. Schmidt, C. *et al.* Clinical features of rapidly progressive Alzheimer's disease. *Dementia and geriatric cognitive disorders* **29**, 371–378, doi: 10.1159/000278692 (2010).
3. Schmidt, C. *et al.* Rapidly progressive Alzheimer disease. *Arch Neurol* **68**, 1124–1130, doi: 10.1001/archneurol.2011.189 (2011).
4. Wattmo, C., Wallin, A. K. & Minthon, L. Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies. *Alzheimer's research & therapy* **5**, 44, doi: 10.1186/alzrt210 (2013).
5. Murray, M. E. *et al.* Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. *The Lancet. Neurology* **10**, 785–796, doi: 10.1016/S1474-4422(11)70156-9 (2011).
6. Noh, Y. *et al.* Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. *Neurology* **83**, 1936–1944, doi: 10.1212/WNL.0000000000001003 (2014).
7. Na, H. K. *et al.* Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. *Neurobiology of aging* **47**, 149–156, doi: 10.1016/j.neurobiolaging.2016.08.001 (2016).
8. Nettiksimmons, J., DeCarli, C., Landau, S. & Beckett, L. & Alzheimer's Disease Neuroimaging, I. Biological heterogeneity in ADNI amnesic mild cognitive impairment. *Alzheimer's Dement* **10**, 511–521 e511, doi: 10.1016/j.jalz.2013.09.003 (2014).
9. Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. *Journal of Statistical Mechanics: Theory and Experiment*. **1000** (2008).
10. O'Bryant, S. E. *et al.* Validation of the new interpretive guidelines for the clinical dementia rating sum of boxes score in the national Alzheimer's coordinating center database. *Arch Neurol* **67**, 746–749, doi: 10.1001/archneurol.2010.115 (2010).
11. O'Bryant, S. E. *et al.* Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. *Arch Neurol* **65**, 1091–1095, doi: 10.1001/archneur.65.8.1091 (2008).
12. Behrmann, M., Geng, J. J. & Shomstein, S. Parietal cortex and attention. *Curr Opin Neurobiol* **14**, 212–217, doi: 10.1016/j.conb.2004.03.012 (2004).
13. Cavanna, A. E. & Trimble, M. R. The precuneus: a review of its functional anatomy and behavioural correlates. *Brain: a journal of neurology* **129**, 564–583, doi: 10.1093/brain/awl004 (2006).
14. Jacobs, H. I., Van Boxtel, M. P., Jolles, J., Verhey, F. R. & Uylings, H. B. Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. *Neurosci Biobehav Rev* **36**, 297–309, doi: 10.1016/j.neubiorev.2011.06.009 (2012).
15. Wagner, A. D., Shannon, B. J., Kahn, I. & Buckner, R. L. Parietal lobe contributions to episodic memory retrieval. *Trends Cogn Sci* **9**, 445–453, doi: 10.1016/j.tics.2005.07.001 (2005).
16. Gross, R. G. & Grossman, M. Update on apraxia. *Current neurology and neuroscience reports* **8**, 490–496 (2008).
17. Itakura, H. *et al.* Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. *Science translational medicine* **7**, 303ra138, doi: 10.1126/scitranslmed.aaa7582 (2015).

18. Makuuchi, M., Kaminaga, T. & Sugishita, M. Brain activation during ideomotor praxis: imitation and movements executed by verbal command. *Journal of neurology, neurosurgery, and psychiatry* **76**, 25–33, doi: 10.1136/jnnp.2003.029165 (2005).
19. Whitwell, J. L. *et al.* Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. *The Lancet. Neurology* **11**, 868–877, doi: 10.1016/S1474-4422(12)70200-4 (2012).
20. Shiino, A. *et al.* Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease. *NeuroImage* **33**, 17–26, doi: 10.1016/j.neuroimage.2006.06.010 (2006).
21. Dong, A., Honnorat, N., Gaonkar, B. & Davatzikos, C. CHIMERA: Clustering of Heterogeneous Disease Effects via Distribution Matching of Imaging Patterns. *IEEE transactions on medical imaging* **35**, 612–621, doi: 10.1109/TMI.2015.2487423 (2016).
22. Duyckaerts, C. Disentangling Alzheimer's disease. *The Lancet. Neurology* **10**, 774–775, doi: 10.1016/S1474-4422(11)70171-5 (2011).
23. Mattsson, N., Schott, J. M., Hardy, J., Turner, M. R. & Zetterberg, H. Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. *Journal of neurology, neurosurgery, and psychiatry*, doi: 10.1136/jnnp-2015-311321 (2016).
24. Didic, M. *et al.* Which memory system is impaired first in Alzheimer's disease? *Journal of Alzheimer's disease: JAD* **27**, 11–22, doi: 10.3233/JAD-2011-110557 (2011).
25. Domoto-Reilly, K., Sapolsky, D., Brickhouse, M. & Dickerson, B. C. & Alzheimer's Disease Neuroimaging, I. Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy. *NeuroImage* **63**, 348–355, doi: 10.1016/j.neuroimage.2012.06.018 (2012).
26. Bruner, E. & Jacobs, H. I. Alzheimer's disease: the downside of a highly evolved parietal lobe? *Journal of Alzheimer's disease: JAD* **35**, 227–240, doi: 10.3233/JAD-122299 (2013).
27. Chiang, M. C. *et al.* Genetics of brain fiber architecture and intellectual performance. *J Neurosci* **29**, 2212–2224, doi: 10.1523/JNEUROSCI.4184-08.2009 (2009).
28. Gour, N. *et al.* Basal functional connectivity within the anterior temporal network is associated with performance on declarative memory tasks. *NeuroImage* **58**, 687–697, doi: 10.1016/j.neuroimage.2011.05.090 (2011).
29. King, K. S. *et al.* Evaluation of a practical visual MRI rating scale of brain white matter hyperintensities for clinicians based on largest lesion size regardless of location. *AJNR Am J Neuroradiol* **34**, 797–801, doi: 10.3174/ajnr.A3283 (2013).
30. Noh, Y. *et al.* A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities. *J Stroke Cerebrovasc Dis* **23**, 636–642, doi: 10.1016/j.jstrokecerebrovasdis.2013.06.002 (2014).
31. Shim, Y. S. *et al.* Effects of medial temporal atrophy and white matter hyperintensities on the cognitive functions in patients with Alzheimer's disease. *Eur Neurol* **66**, 75–82, doi: 10.1159/000329277 (2011).
32. Laakso, M. P. *et al.* Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions. *Journal of Neural Transmission - Parkinson's Disease and Dementia Section* **9**, 73–86, doi: 10.1007/bf02252964 (1995).
33. Jack, C. R. Jr. *et al.* The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *Journal of magnetic resonance imaging: JMRI* **27**, 685–691, doi: 10.1002/jmri.21049 (2008).
34. Kukull, W. A. *et al.* The Mini-Mental State Examination score and the clinical diagnosis of dementia. *J Clin Epidemiol* **47**, 1061–1067 (1994).
35. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* **74**, 201–209, doi: 10.1212/WNL.0b013e3181cb3e25 (2010).
36. Kang, Y. W. & Na, D. L. *Seoul Neuropsychological Screening Battery: Professional Manual*. (Human Brain Research & Consulting Co., 2003).
37. Kang, Y. W., Chang, S. M. & Na, D. L. *Seoul Neuropsychological Screening Battery: Professional Manual*. 2 edn, (Human Brain Research & Consulting Co., 2012).
38. Kim, H. & Na, D. L. Normative data on the Korean version of the Boston Naming Test. *Journal of clinical and experimental neuropsychology* **21**, 127–133, doi: 10.1076/jcen.21.1.127.942 (1999).
39. Mueller, S. G. *et al.* Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Alzheimers Dement* **1**, 55–66, doi: 10.1016/j.jalz.2005.06.003 (2005).
40. Park, L. Q. *et al.* Confirmatory factor analysis of the ADNI Neuropsychological Battery. *Brain Imaging Behav* **6**, 528–539, doi: 10.1007/s11682-012-9190-3 (2012).
41. Mohs, R. C. *et al.* Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. *Alzheimer Dis Assoc Disord* **11** Suppl 2, S13–21 (1997).
42. Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer's disease. *Am J Psychiatry* **141**, 1356–1364 (1984).
43. Mack, W. J., Freed, D. M., Williams, B. W. & Henderson, V. W. Boston Naming Test: shortened versions for use in Alzheimer's disease. *J Gerontol* **47**, P154–158 (1992).
44. Barzotti, T. *et al.* Correlation between cognitive impairment and the Rey auditory-verbal learning test in a population with Alzheimer disease. *Arch Gerontol Geriatr Suppl*. 57–62, doi: 10.1016/j.archger.2004.04.010 (2004).
45. van Hout, H. & Berkhout, S. Inter-rater reliability of the clock-drawing test. *Age Ageing* **28**, 327–328 (1999).
46. Bowie, C. R. & Harvey, P. D. Administration and interpretation of the Trail Making Test. *Nat Protoc* **1**, 2277–2281, doi: 10.1038/nprot.2006.390 (2006).
47. Tombaugh, T. N. Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol* **19**, 203–214, doi: 10.1016/S0887-6177(03)00039-8 (2004).
48. Lezak, M. D. *Neuropsychological Assessment*. 3 edn, (Oxford University Press, 1995).
49. Gibbons, L. E. *et al.* A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging Behav* **6**, 517–527, doi: 10.1007/s11682-012-9176-1 (2012).
50. Crane, P. K. *et al.* Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav* **6**, 502–516, doi: 10.1007/s11682-012-9186-z (2012).
51. Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. *NeuroImage* **9**, 179–194 (1999).
52. Dale, A. M. & Sereno, M. I. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: a linear approach. *J Cogn Neurosci* **5**, 162–176 (1993).
53. Cho, Y., Seong, J. K., Jeong, Y., Shin, S. Y. & Alzheimer's Disease Neuroimaging, I. Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data. *NeuroImage* **59**, 2217–2230, doi: 10.1016/j.neuroimage.2011.09.085 (2012).
54. Levy, B. In SMI'06: Proceedings of the IEEE International Conference on Shape Modeling and Applications 2006. 13 (IEEE Computer Society).
55. Qiu, A., Bitouk, D. & Miller, M. Smooth functional and structural maps on the neocortex via orthonormal bases of the Laplace-Beltrami operator. *IEEE Trans. Med. Imaging* **25**, 1296–1306 (2006).
56. Rubinov, M. & Sporns, O. Complex network measures of brain connectivity: Uses and interpretations. *NeuroImage* **52**, 1059–1069, doi: S1053-8119(09)01074-X [pii] 10.1016/j.neuroimage.2009.10.003 (2010).
57. Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* **31**, 968–980 (2006).

58. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*, 289–300 (1995).
59. Genovese, C. R., Lazar, N. A. & Nichols, T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *NeuroImage* 15, 870–878 (2002).
60. Poline, J. B., Worsley, K. J., Evans, A. C. & Friston, K. J. Combining spatial extent and peak intensity to test for activations in functional imaging. *NeuroImage* 5, 83–96, doi: 10.1006/nimg.1996.0248 (1997).

Acknowledgements

This research was supported by the Basic Science Research Program (MSIP-2014-R1A1A1008173), Institute for Information & communications Technology Promotion(IITP) grant funded by the Korea government(MSIP) (No. B0101–15–247, Development of Open ICT Healing Platform using Personal Health Data), and the Original Technology Research Program for Brain Science through the National Research Foundation of Korea(NRF) funded by the Ministry of Science ICT and Future Planning (2015M3C7A1029034). Data collection and sharing for this project was funded by ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) via the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis International AG; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company Ltd; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego.

Author Contributions

J.K.S. and C.E.H. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: J.K.S., C.E.H., J.Y.P., and H.K.N. Data acquisition: D.L.N., S.W.S., and A.D.N.I. Analysis of imaging data and interpretation: J.Y.P., H.K.N., S.S.K., H.W.K., and H.J.K. Statistical analysis: J.Y.P., and H.K.N. Drafting of the manuscript: J.K.S., C.E.H., J.Y.P., and H.K.N.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Park, J.-Y. *et al.* Robust Identification of Alzheimer's Disease subtypes based on cortical atrophy patterns. *Sci. Rep.* 7, 43270; doi: 10.1038/srep43270 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017

Consortia

Alzheimer's Disease Neuroimaging Initiative

Michael Weiner⁶, Paul Aisen⁷, Ronald Petersen⁸, Clifford R. Jack⁸, William Jagust⁹, John Q. Trojanowski¹⁰, Arthur W. Toga¹¹, Laurel Beckett¹², Robert C. Green¹³, Andrew J. Saykin¹⁴, John Morris¹⁵, Leslie M. Shaw¹⁰, Enchi Liu¹⁶, Tom Montine¹⁷, Ronald G. Thomas⁷, Michael Donohue⁷, Sarah Walter⁷, Devon Gessert⁷, Tamie Sather⁷, Gus Jiminez⁷, Danielle Harvey¹², Matthew Bernstein⁸, Nick Fox¹⁸, Paul Thompson¹¹, Norbert Schuff⁶, Charles DeCarli¹², Bret Borowski⁸, Jeff Gunter⁸, Matt Senjem⁸, Prashanthi Vemuri⁸, David Jones⁸, Kejal Kantarci⁸, Chad Ward⁸, Robert A. Koeppe¹⁹, Norm Foster²⁰, Eric M. Reiman²¹, Kewei Chen²¹, Chet Mathis²², Susan Landau⁹, Nigel J. Cairns¹⁵, Erin Householder¹⁵, Lisa Taylor Reinwald¹⁵, Virginia Lee²³, Magdalena Korecka²³, Michal Figurski²³, Karen Crawford¹¹, Scott Neu¹¹, Tatiana M. Foroud¹⁴, Steven G. Potkin²⁴, Li Shen¹⁴, Faber Kelley¹⁴, Sungeun Kim¹⁴, Kwangsik Nho¹⁴, Zaven Kachaturian^{25,26}, Richard Frank²⁷, Peter J. Snyder²⁸, Susan Molchan^{29,30}, Jeffrey Kaye³¹, Joseph Quinn³¹, Betty Lind³¹, Raina Carter³¹, Sara Dolen³¹, Lon S. Schneider³², Sonia Pawluczuk³², Mauricio Beccera³², Liberty Teodoro³², Bryan M. Spann³², James Brewer⁷, Helen Vanderswag⁷, Adam Fleisher^{7,21}, Judith L. Heidebrink¹⁹, Joanne L. Lord¹⁹, Sara S. Mason⁸, Colleen S. Albers⁸, David Knopman⁸, Kris Johnson⁸, Rachelle S. Doody³³, Javier Villanueva Meyer³³, Munir Chowdhury³³, Susan Rountree³³, Mimi Dang³³, Yaakov Stern³⁴, Lawrence S. Honig³⁴, Karen L. Bell³⁴, Beau Ances¹⁵, Maria Carroll¹⁵, Sue Leon¹⁵, Mark A. Mintun¹⁵, Stacy Schneider¹⁵, Angela Oliver¹⁵, Daniel Marson³⁵, Randall Griffith³⁵, David Clark³⁵, David Geldmacher³⁵, John Brockington³⁵, Erik Roberson³⁵, Hillel Grossman³⁶, Effie Mitsis³⁶, Leyla deToledo-Morrell³⁷, Raj C. Shah³⁷, Ranjan Duara³⁸, Daniel Varon³⁸, Maria T. Greig³⁸, Peggy Roberts³⁸, Marilyn Albert³⁹, Chiadi Onyike³⁹, Daniel D'Agostino II³⁹, Stephanie Kielb³⁹, James E. Galvin⁴⁰, Dana M. Pogorelec⁴⁰, Brittany Cerbone⁴⁰, Christina A. Michel⁴⁰, Henry Rusinek⁴⁰, Mony J. de Leon⁴⁰, Lidia Glodzik⁴⁰, Susan De Santi⁴⁰, P. Murali Doraiswamy⁴¹, Jeffrey R. Petrella⁴¹, Terence Z. Wong⁴¹, Steven E. Arnold¹⁰, Jason H. Karlawish¹⁰, David Wolk¹⁰, Charles D. Smith⁴², Greg Jicha⁴², Peter Hardy⁴², Partha Sinha⁴², Elizabeth Oates⁴², Gary Conrad⁴², Oscar L. Lopez²², MaryAnn Oakley²², Donna M. Simpson²², Anton P. Porsteinsson⁴³, Bonnie S. Goldstein⁴³, Kim Martin⁴³, Kelly M. Makino⁴³, M. Saleem Ismail⁴³, Connie Brand⁴³, Ruth A. Mulnard²⁴, Gaby Thai²⁴, Catherine Mc Adams Ortiz²⁴, Kyle Womack⁴⁴, Dana Mathews⁴⁴, Mary Quiceno⁴⁴, Ramon Diaz Arrastia⁴⁴, Richard King⁴⁴, Myron Weiner⁴⁴, Kristen Martin Cook⁴⁴, Michael DeVous⁴⁴, Allan I. Levey⁴⁵, James J. Lah⁴⁵, Janet S. Cellar⁴⁵, Jeffrey M. Burns⁴⁶, Heather S. Anderson⁴⁶, Russell H. Swerdlow⁴⁶, Liana Apostolova¹¹, Kathleen Tingus¹¹, Ellen Woo¹¹, Daniel H. S. Silverman¹¹, Po H. Lu¹¹, George Bartzokis¹¹, Neill R. Graff Radford⁴⁷, Francine Parfitt⁴⁷, Tracy Kendall⁴⁷, Heather Johnson⁴⁷, Martin R. Farlow¹⁴, Ann Marie Hake¹⁴, Brandy R. Matthews¹⁴, Scott Herring¹⁴, Cynthia Hunt¹⁴, Christopher H. van Dyck⁴⁸, Richard E. Carson⁴⁸, Martha G. MacAvoy⁴⁸, Howard Chertkow⁴⁹, Howard Bergman⁴⁹, Chris Hosein⁴⁹, Sandra Black⁵⁰, Bojana Stefanovic⁵⁰, Curtis Caldwell⁵⁰, Ging Yuek Robin Hsiung⁵¹, Howard Feldman⁵¹, Benita Mudge⁵¹, Michele Assaly⁵¹, Dick Trost⁵², Charles Bernick⁵³, Donna Munic⁵³, Diana Kerwin⁵⁴, Marek Marsel Mesulam⁵⁴, Kristine Lipowski⁵⁴, Chuang Kuo Wu⁵⁴, Nancy Johnson⁵⁴, Carl Sadowsky⁵⁵, Walter Martinez⁵⁵, Teresa Villena⁵⁵, Raymond Scott Turner⁵⁶, Kathleen Johnson⁵⁶, Brigid Reynolds⁵⁶, Reisa A. Sperling¹³, Keith A. Johnson¹³, Gad Marshall¹³, Meghan Frey¹³, Jerome Yesavage⁵⁷, Joy L. Taylor⁵⁷, Barton Lane⁵⁷, Allyson Rosen⁵⁷, Jared Tinklenberg⁵⁷, Marwan N. Sabbagh⁵⁸, Christine M. Belden⁵⁸, Sandra A. Jacobson⁵⁸, Sherye A. Sirrel⁵⁸, Neil Kowall⁵⁹, Ronald Killiany⁵⁹, Andrew E. Budson⁵⁹, Alexander Norbash⁵⁹, Patricia Lynn Johnson⁵⁹, Thomas O. Obisesan⁶⁰, Saba Wolday⁶⁰, Joanne Allard⁶⁰, Alan Lerner⁶¹, Paula Ogrocki⁶¹, Leon Hudson⁶¹, Evan Fletcher¹², Owen Carmichael¹², John Olichney¹², Smita Kittur⁶², Michael Borrie⁶³, T. Y. Lee⁶³, Rob Bartha⁶³, Sterling Johnson⁶⁴, Sanjay Asthana⁶⁴, Cynthia M. Carlsson⁶⁴, Adrian Preda²⁴, Dana Nguyen²⁴, Pierre Tariot²¹, Stephanie Reeder²¹, Vernice Bates⁶⁵, Horacio Capote⁶⁵, Michelle Rainka⁶⁵, Douglas W. Scharre⁶⁶, Maria Katakis⁶⁶, Anahita Adeli⁶⁶, Earl A. Zimmerman⁶⁷, Dzintra Celmins⁶⁷, Alice D. Brown⁶⁷, Godfrey D. Pearlson⁶⁸, Karen Blank⁶⁸, Karen Anderson⁶⁸, Robert B. Santulli⁶⁹, Tamar J. Kitzmiller⁶⁹, Eben S. Schwartz⁶⁹, Kaycee M. Sink⁷⁰, Jeff D. Williamson⁷⁰, Pradeep Garg⁷⁰, Franklin Watkins⁷⁰, Brian R. Ott⁷¹, Henry Querfurth⁷¹, Geoffrey Tremont⁷¹, Stephen Salloway⁷², Paul Malloy⁷², Stephen Correia⁷², Howard J. Rosen⁶, Bruce L. Miller⁶, Jacobo Mintzer⁷³, Kenneth Spicer⁷³, David Bachman⁷³, Elizabeth Finger⁷⁴, Stephen Pasternak⁷⁴, Irina Rachinsky⁷⁴, John Rogers⁷⁴, Andrew Kertesz^{52,74}, Nunzio Pomara⁷⁵, Raymundo

Hernando⁷⁵, Antero Sarrael⁷⁵, Susan K. Schultz⁷⁶, Laura L. Boles Ponto⁷⁶, Hyungsub Shim⁷⁶, Karen Elizabeth Smith⁷⁶, Norman Relkin⁷⁷, Gloria Chaing⁷⁷, Lisa Raudin⁷⁷, Amanda Smith⁷⁸, Kristin Fargher⁷⁸ & Balebail Ashok Raj⁷⁸

⁶UC San Francisco, San Francisco, USA. ⁷UC San Diego, La Jolla, USA. ⁸Mayo Clinic, Rochester, MN USA. ⁹UC Berkeley, Berkeley, San Francisco, USA. ¹⁰University of Pennsylvania, Philadelphia, PA USA. ¹¹USC School of Medicine, Los Angeles, CA, USA. ¹²University of California, Davis Sacramento, Sacramento, CA, USA. ¹³Brigham and Women's Hospital, Boston, MA, USA. ¹⁴Indiana University, Bloomington, IN USA. ¹⁵Washington University St. Louis, MO, USA. ¹⁶Janssen Alzheimer Immunotherapy, San Francisco, USA. ¹⁷University of Washington, Seattle, WA, USA. ¹⁸University of London, London, UK. ¹⁹University of Michigan, Ann Arbor, MI, USA. ²⁰University of Utah, Salt Lake City, UT, USA. ²¹Banner Alzheimer's Institute, Phoenix, AZ, USA. ²²University of Pittsburgh, Pittsburgh, PA, USA. ²³University of Pennsylvania School of Medicine, Philadelphia, PA, USA. ²⁴University of California Irvine, Irvine, CA, USA. ²⁵Khachaturian, Radebaugh & Associates, Inc, USA. ²⁶Ronald and Nancy Reagan's Research Institute, Chicago, IL, USA. ²⁷General Electric, USA. ²⁸Brown University, Providence, RI, USA. ²⁹National Institute on Aging, Baltimore, Maryland, USA. ³⁰National Institutes of Health, USA. ³¹Oregon Health and Science University, Portland, OR, USA. ³²University of Southern California, Los Angeles, CA, USA. ³³Baylor College of Medicine, Houston, TX, USA. ³⁴Columbia University Medical Center, New York, NY, USA. ³⁵University of Alabama Birmingham, Birmingham, AL, USA. ³⁶Mount Sinai School of Medicine, New York, NY, USA. ³⁷Rush University Medical Center, Chicago, IL, USA. ³⁸Wien Center, Miami Beach, FL, USA. ³⁹Johns Hopkins University, Baltimore, MD, USA. ⁴⁰New York University, New York, NY, USA. ⁴¹Duke University Medical Center, Durham, NC, USA. ⁴²University of Kentucky, Lexington, KY, USA. ⁴³University of Rochester Medical Center, Rochester, NY, USA. ⁴⁴University of Texas Southwestern Medical School, Dallas, TX, USA. ⁴⁵Emory University, Atlanta, GA, USA. ⁴⁶University of Kansas, Medical Center, Kansas City, KS, USA. ⁴⁷Mayo Clinic, Jacksonville, Florida, USA. ⁴⁸Yale University School of Medicine, New Haven, CT, USA. ⁴⁹McGill Univ., Montreal Jewish General Hospital, Montreal, QC, Canada. ⁵⁰Sunnybrook Health Sciences, Toronto, ON, Canada. ⁵¹U.B.C. Clinic for AD & Related Disorders, Vancouver, BC, Canada. ⁵²Cognitive Neurology St. Joseph's, Ontario, ON, Canada. ⁵³Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. ⁵⁴Northwestern University, Evanston, IL, USA. ⁵⁵Premiere Research Inst, West Palm Beach, FL, USA. ⁵⁶Georgetown University Medical Center, Washington, DC, USA. ⁵⁷Stanford University, Stanford, CA, USA. ⁵⁸Banner Sun Health Research Institute, Sun City, AZ, USA. ⁵⁹Boston University, Boston, MA, USA. ⁶⁰Howard University, Washington, DC, USA. ⁶¹Case Western Reserve University, Cleveland, OH, USA. ⁶²Neurological Care of CNY, Liverpool, NY, USA. ⁶³Parkwood Hospital, London, ON, Canada. ⁶⁴University of Wisconsin, Madison, WI, USA. ⁶⁵Dent Neurologic Institute, Amherst, NY, USA. ⁶⁶Ohio State University, Columbus, OH, USA. ⁶⁷Albany Medical College, Albany, NY, USA. ⁶⁸Hartford Hosp, Olin Neuropsychiatry Research Center, Hartford, CT, USA. ⁶⁹Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. ⁷⁰Wake Forest University Health Sciences, Winston-Salem, NC, USA. ⁷¹Rhode Island Hospital, Providence, RI, USA. ⁷²Butler Hospital, Providence, RI, USA. ⁷³Medical University South Carolina, Charleston, SC, USA. ⁷⁴St. Joseph's Health Care, Irvine, CA, USA. ⁷⁵Nathan Kline Institute, Orangeburg, NY, USA. ⁷⁶University of Iowa College of Medicine, Iowa City, Iowa City, IA, USA. ⁷⁷Cornell University, Ithaca, NY, USA. ⁷⁸University of South Florida: USF Health Byrd Alzheimer's Institute, Tampa, FL, USA.